多组学揭示CD7 CAR-T后从CD7阴性T细胞失调到EBV阳性LPD的演变
本研究针对CD7 CAR-T治疗后出现的EBV阳性淋巴增殖性疾病(PCLD),采用单核RNA测序、ATAC测序和Stereo-seq进行多组学空间分析,并与经典移植后淋巴增殖性疾病、EBV阴性弥漫大B细胞淋巴瘤及正常淋巴结比较。发现PCLD浸润T细胞呈CD7阴性、抗EBV活性受损,Macro_IDO1巨噬细胞亚群形成免疫抑制微环境,限制T细胞浸润并促进EBV驱动B细胞恶性转化。
要点
- CD7 CAR-T后EBV激活可导致EBV阳性淋巴增殖性疾病(PCLD)。
- PCLD中浸润T细胞CD7阴性且抗EBV功能受损。
- Macro_IDO1巨噬细胞聚集形成免疫抑制微环境促进肿瘤转化。
核心结论
- CD7 CAR-T治疗后EBV激活可进展为EBV阳性淋巴增殖性疾病(PCLD),其发生与CD7阴性T细胞失调及免疫抑制微环境相关。
研究设计与样本
- 采用单核RNA测序、ATAC测序和Stereo-seq对PCLD进行多组学空间分析,并与经典移植后淋巴增殖性疾病、EBV阴性弥漫大B细胞淋巴瘤及正常淋巴结比较。
主要发现
- PCLD浸润T细胞呈CD7阴性,感染刺激后增殖有限,抗EBV活性受损。
- Macro_IDO1巨噬细胞亚群为优势巨噬细胞群体,高表达IDO1并呈免疫抑制表型。
- 巨噬细胞(主要为Macro_IDO1)聚集形成免疫抑制微环境,限制T细胞浸润并富集PD-1/PD-L1等抑制性配体-受体相互作用。
- EBV驱动的B细胞发生浆细胞样分化并持续增殖,主动重塑微环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
EBV activation specifically occurs in a subset of patients following CD7 CAR-T therapy, subsequently leading to EBV-positive lymphoproliferative disorder (EBV+ LPD), descriptively referred to as post-CD7 CAR-T lymphoproliferative disorder (PCLD) in this study. To comprehensively characterize PCLD, we employed single-nucleus RNA sequencing, ATAC sequencing, and Stereo-seq to perform multi-omic spatial profiling of PCLD, and compared it with classical post-transplant lymphoproliferative disorder (PTLD), EBV-negative diffuse large B-cell lymphoma (EBV- DLBCL) and normal lymph nodes. Infiltrating T cells in PCLD are uniquely characterized by CD7 negativity, exhibiting limited proliferation upon infection stimulation and impaired antiviral activity against EBV. Macrophages are recruited in an attempt to sustain viral clearance; however, the Macro_IDO1 subset emerges as the dominant macrophage population, exhibiting an immunosuppressive phenotype marked by elevated IDO1 expression. Spatially, macrophages, predominantly Macro_IDO1, aggregate to form an immunosuppressive niche that restricts T-cell infiltration and is enriched for inhibitory ligand-receptor interactions, including the PD-1/PD-L1 axis. T-cell function is further compromised, enabling sustained EBV infection of B cells and driving malignant transformation. EBV-driven B cells undergo plasmacytic differentiation and sustained proliferation, actively remodeling the microenvironment. This study provides a comprehensive molecular characterization of lymphoproliferative disorder following CD7 CAR-T therapy, elucidates spatial tumor-immune interactions, mechanisms of EBV-driven B-cell transformation and potential intervention strategies.
引用
- Huang M, Jiang Y, Ye F, et al. Multi-omics reveals evolution from CD7-negative T cell dysregulation to EBV-positive LPD after CD7 CAR-T therapy. Blood. 2026. PMID: 42950083. doi:10.1182/blood.2026034648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。